ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0980

The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc

Kourtney Rudzinski1, Zaina Shahid2, Yasin kanakrieh2, Saloni Goyal2, Kyle Shaak2 and James Ross3, 1Lehigh Valley Health Network, Tatamy, PA, 2Lehigh Valley Health Network, Allentown, PA, 3lvhn, Macungie, PA

Meeting: ACR Convergence 2022

Keywords: Drug toxicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Hydroxychloroquine (HCQ) has faced increased scrutiny during the COVID pandemic for its association with QTc prolongation. In our field, patients are commonly on antidepressant medications that can further increase these risks. Our goal in this study was to see if HCQ in combination with antidepressants was associated with increased risk of QTc prolongation or increased life-threatening arrhythmias or sudden cardiac death (SCD). We have also gathered data on confounding variables such as concomitant use of anti-arrhythmics, antibiotics, antifungals, as well as the presence of CHF and CAD.

Methods: A retrospective chart review from March 15 2015 to May 12 2021 gathered 949 records of patients on HCQ for more than 1 month, over the age of 18, and with an EKG documented while on HCQ. Descriptive statistics were used to summarize the demographic characteristics of the study sample, including patient demographics and clinical baseline characteristics. The primary analysis of the study was a two-step process utilizing the chi-square test of independence and binomial logistic regression. Chi-square analyses were used to test for associations between demographic and clinical variables and the outcome of a prolonged QTc. Variables that were included in this stage were gender, race, ethnicity, actively taking antidepressants, actively taking anti-arrhythmics and renal and/or hepatic disease. If bivariate analysis resulted in a p-value less than 0.25 the variable was included in logistic regression analysis. Additional chi-square tests were used to compare a diagnosed prolonged QTc based on antidepressant prescription, as well as renal or hepatic disease.

Results: All variables included in the logistic regression model were found to be significantly associated with a prolonged QTc at the 5% significance level: CAD, CHF, actively taking antidepressants, actively taking anti-arrhythmics and renal and/or hepatic disease. The odds of having prolonged QTc while on HCQ was highest among those taking anti-arrhythmics, followed by those with CHF, then presence of hepatic or renal disease, then presence of CAD, and lastly followed by patients on antidepressants. The electrolyte abnormality most frequently associated with prolonged QTc was hypokalemia. Patients taking antidepressants had a significantly higher chance of a prolonged QTc but no significant difference was seen for life-threatening arrhythmia or SCD.

Conclusion: While our study did have limitations, it demonstrated that antidepressant use with HCQ was associated with prolonged QTc but did not increase life-threatening arrhythmias or SCD. Our results showed the highest risks for QTc prolongation were in patients on anti-arrhymthics, followed by patients with CHF, and then patients with hepatic or renal disease. Therefore, special considerations might need to be considered in these populations. Future studies can assess benefits of baseline EKGs to determine if adding HCQ results in new or worsening QTc in higher risk populations.

References:

1. Dietle, A. (2015). QTc Prolongation With Antidepressants and Antipsychotics. US Pharm, 40(11), HS34-HS40.

Supporting image 1

Table 1. Hydroxychloroquine Prescribing and Other Medications

Supporting image 2

Table 2. Clinical Outcomes

Supporting image 3

Table 3. Odds Ratio for Factors Associated with Prolonged QTc


Disclosures: K. Rudzinski, None; Z. Shahid, None; Y. kanakrieh, None; S. Goyal, None; K. Shaak, None; J. Ross, None.

To cite this abstract in AMA style:

Rudzinski K, Shahid Z, kanakrieh Y, Goyal S, Shaak K, Ross J. The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-effect-and-outcomes-of-hcq-alone-and-in-combination-with-anti-depressants-on-qtc/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-and-outcomes-of-hcq-alone-and-in-combination-with-anti-depressants-on-qtc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology